MXPA96006179A - Agonists and antagonists of the receptors of the nicotinic acid acetilcoline of insects for the control of endoparasi - Google Patents

Abstract

Use of agonists and antagonists of the nicotinérgicos receptors of the acetylcholine of the insects for the fight against the endoparásit

Description

AGONISTS AND ANTAGONISTS OF THE RECEIVERS OF THE NICOTINIC INSECT ACETILCOLINE ACID FOR THE CONTROL OF ENDOPERASITES DESCRIPTION OF THE INVENTION The present invention relates to the fight against endoparasites by means of agonists or antagonists of the nicotinergic receptors of the acetylcholine of insects. The agonists or antagonists of the nicotinergic receptors of the acetylcholine of insects are known. These include the nicotinylated insecticides and especially the chloronicotinilic insecticides. It is also known that these compounds have an excellent action against the harmful insects of plants. The systemic effect of these compounds is also known in plants against insects harmful to plants. It is known from the PCT application WO 93/24 002 that certain l- [N- (halo-3-pyridylmethyl)] -N-methylamino-1-alkylamino-2-nitroethylene derivatives are suitable for systemic use against lice in animals. of schools. In this type of application the active product is administered to the pet orally or parenterally, for example by injection and thus reaches the blood supply of the pet. The lice then absorb the active product when they suck the blood. However, nothing has been reported about the effect of REF: 23532 these compounds against the endoparasites. It has now surprisingly been found that agonists or antagonists of nicotinic acid acetylcholine receptors are suitable for the control against endoparasites. Agonists or antagonists of the nicotinogenic receptors of the acetylcholine of insects are known, for example, from the descriptions of the published German patent applications Nos. 464 830, 428 941, 425 978, 386 565, 383 091, 375 907, 364 844, 315 826, 259 738, 254 859, 235 725, 212 600, 192 060, 163 855, 154 178, 136 636, 303 570, 302 833, 306 696, 189 972, 455 000, 135 956, 471 372 , 302 389; descriptive reports of published European patent applications, not examined, numbers 3 639 877, 3 712 307; Descriptive reports of Japanese patent applications published, not examined numbers 03 220 176, 02 207 083, 63 307 857, 63 287 764, 03 246 283, 04 9371, 03 279 359, 03 255 072; descriptive reports of US Pat Nos. 5 034 524, 4 948 798, 4 918 086, 5 039 686, 5 034 404; PCT applications numbers WO 91/17 659, 91/4965; French application No. 2 611 114; Brazilian application nc 88 03 621. Reference will be made expressly in this case to the methods, procedures, formulas and definitions described in these publications as well as the preparations and individual compounds described therein. These compounds can be represented preferably by means of the general formula (I) wherein R means hydrogen, optionally substituted radicals of the group consisting of acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; A means a monofunctional group of the group consisting of hydrogen, acyl, alkyl, aryl or means a bifunctional group, which is linked to the radical Z; E means an electrophilic residue; X means the remainder -CH = or = N-, where the residue -CH = may be linked to the residue Z instead of an H atom; Z means a monofunctional group of the group consisting of alkyl, -O-R, -S-R, R / N or means a bifunctional group, which is linked to the remainder A or to the rest X. Particularly preferred are the compounds of the formula (I), in which the radicals have the following meaning: R means hydrogen as well as residues, given substituted, from the group consisting of acyl, alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl. Acyl radicals include formyl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl- (alkyl-) - (aryl-) phosphoryl, which, in turn, can be substituted. As alkyl, there may be mentioned alkyl having 1 to 10 carbon atoms, especially alkyl having 1 to 4 carbon atoms, in particular methyl, ethyl, i-propyl, sec- or t. -butyl, which in turn may be replaced. As the aryl, phenyl, naphthyl, especially phenyl, may be mentioned. As the aralkyl, phenylmethyl, phenethyl can be mentioned. As heteroaryl, heteroaryl with up to 10 ring carbon atoms and special N, O, S may be mentioned N as heteroatoms. In particular, thienyl, furyl, thiazolyl, imidazolyl, pyridyl, benzo-thiazolyl may be mentioned. As heteroarylalkyl, heteroaryl-methyl, heteroarylethyl with up to 6 ring atoms and N, 0, S, especially N, may be mentioned as heteroatoms. Examples which may be mentioned as substituents are preferably: alkyl having preferably 1 to 4 atoms, especially 1 or 2 carbon atoms, such as methyl, ethyl, n- and i-propyl, and n-, i- and t-butyl, • alkoxy with preferably 1 to 4, especially 1 or 2 carbon atoms, such as methoxy, ethoxy, n- and i-propyl-oxy and n-, e- and t-butyloxy; alkylthio with preferably 1 to 4, especially 1 or 2 carbon atoms, such as methylthio, ethylthio, n- and i-propylthio and n-, i- and t-butylthio; haloalkyl with preferably 1 to 4, especially 1 or 2 carbon atoms and preferably 1 to 5, in particular 1 to 3 halogen atoms, the halogen atoms being the same or different and the halogen atoms preferably being fluorine, chlorine or bromine, especially fluorine, such as trifluoromethyl; hydroxy; halogen, preferably fluorine, chlorine, bromine and iodine, especially fluorine, chlorine and bromine; cyano; nitro; Not me; monoalkyl- and dialkylamino with preferably 1 to 4, especially 1 or 2 carbon atoms in each alkyl group, such as tilamino, methyl-ethyl-amino, n- and i-propylamino and methyl-n-butylamino; carboxyl; carbalkoxy with preferably 2 to 4, especially 2 or 3 carbon atoms, such as carbome-toxy and carboethoxy; sulfo (-SO3H); alkylsulfonyl with preferentially 1 to 4, especially 1 or 2 carbon atoms, such as methylsulfophenyl and ethylsulfonyl; arylsulfonyl with preferably 6 or 10 carbon atoms in the aryl, such as phenylsulfonyl or heteroarylamino and heteroarylalkyl amino such as chloropyridylamino and chloropyridylmethylamino. A is particularly preferably hydrogen, as well as, optionally substituted radicals, of the group consisting of acyl, alkyl, aryl, which preferably have the meanings indicated in the case of R. A further denotes a bifunctional group. There can be mentioned, in the given case, alkylene substituted with 1 to 4, especially 1 to 2 carbon atoms, the substituents listed above being mentioned as substituents and the alkylene groups being interrupted by heteroatoms of the group consisting of N, O, S. A and Z they can form together with the atoms, with which they are bound, a saturated or unsaturated heterocyclic ring, the heterocyclic ring having one or two heteroatoms and / or heterogroups more the same or different, as heteroatoms preferably meaning oxygen, sulfur or nitrogen and as hetero groups N -to the- chyl, wherein alkyl of the N-alkyl group preferably contain from 1 to 4, especially 1 or 2 carbon atoms. As alkyl, there may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6 members in the ring. Examples of the heterocyclic ring which may be mentioned are pyrrolidine, piperidine, piperazine, hexamethyleneimine, hexahydro-1,3,5-triazine, morpholine, which may optionally be substituted by methyl. E means an electrophilic residue, it being possible to mention especially N02, CN, haloalkylcarbonyl such as 1,5-ha-linocarbonyl with 1 to 4 carbon atoms, especially COCF3. X means -CH = o or -N =. Z means radicals, optionally substituted, alkyl, -OR, -SR, -NRR, where R and the substituents preferably have the meaning indicated above. Z can form, in addition to the aforementioned ring, together with the atom, with which it is bound and with the rest I instead of X a saturated or unsaturated heterocyclic ring. The heterocyclic ring may contain one or two heteroatoms and / or heterogroups more the same or different.

As heteroatoms they preferably mean oxygen, sulfur or nitrogen and as N-alkyl hetero groups, wherein the alkyl of the N-alkyl group preferably contains from 1 to 4, especially 1 or 2 carbon atoms. As the alkyl may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6 members in the ring. Examples of the heterocyclic ring which may be mentioned are pyrrolidine, piperidine, piperazine, hexamethylene-na, morpholine and N-methylpiperazine. The compounds of the general formulas (II) and (III) can be mentioned as compounds which can be used in a very particularly preferred manner according to the invention. where n means 1 or 2, Subst. means one of the substituents above indicated, especially means halogen, very especially chlorine, A, Z, X and E have the meanings indicated above. In particular, the following compounds may be mentioned: CH, CN The active products are suitable, with a toxicity favorable to mammals, for the control of pathogenic endoparasites in man and in the maintenance and breeding of useful animals, breeding, zoo, laboratory, testing and entertainment. In this case they are active against all stages of development or against individual stages of development of pests as well as against resistant and normally sensitive types. The fight against pathogenic endoparasites reduces diseases, death chaos and loss of performance (for example in the production of of meat, milk, wool, skins, eggs, honey, etc.) as well as, if necessary, also the transmission to humans, so that the use of the active products makes it possible to maintain the animals more economically And simple. Pathogenic endoparasites belong to cesto-dos, trematodes, nematodes, especially: from the class of Pseudophyllidia, for example: Diphyllo-bothrium spp. , Spirometra spp. , Schistocephalus spp. , Lígula spp., Bothridium spp., Diphlogonoorus spp. From the class of Cyclofilideos for example: Mesocestoides spp., Anoplocephala spp., Paranoplocephala spp., Moniezia spp., Thysanosmsa spp., Thysaniezia spp., Avitellina spp., Stilesia spp., Cittotaenia spp., Anhyra spp., Bertiella spp., Taenia spp., Echinococcus spp., Hydratigera spp., Davainea spp., Raillietina spp., Hy enolepsis spp., Echinolepsis spp., Echinocotyle spp., Diorchis spp., Dipylidium spp., Joyeuxiella spp., Diplopylidium spp. From the subclass of the Monogeneans for example: Cyrodactylus spp., Dactylogyrus spp., Polystoma spp. From the subclass of the Digéneos, for example: Diplostomum spp., Posthodiplostomum spp., Schistosoma spp., Trichobilharzia spp., Ornithobilharzia spp., Austrobilharzia spp., Gigantobilharzia spp., Leucochloridium spp., Brachylaima spp., Echinostoma spp. , Echinoparyphium spp. , Echinochas us spp., Hypoderaeum spp., Fasciola spp., Fasciolides spp., Fasciolopsis spp. , Cyclocoelum spp. , Typhloccelum spp. , Pa-ra phistomum spp. , Calicophron spp. , Cotylophoron spp. , Gi-gantocotyle spp., Fischoederius spp., Gastrothylacus spp., Notocotylus spp., Catatropis spp., Plagiorchis spp., Pros-thogonismus spp., Dicrocoelium spp., Collyriclum spp., Na-nophyetus spp., Opisthorchis spp. , Clonorchis spp., Metor-chis spp., Heterophyes spp., Metagonimus spp. From the class of Enoplideans, for example: Trichuris spp., Capillaria spp., Trichlomosoides spp., Trichinella spp. From the class of Rhabditios, for example: Micronema spp., Strongyloides spp. From the class of Stromelidae, for example: Stronylus spp., Triodontophorus spp., Oesophagodontus spp., Trichonea spp., Gyalocephalus spp., Cylindropharynx spp., Postériosrromum spp., Cyclococercus spp., Cylicostephanus spp., Oesophagostomum spp., Chabertia spp., Stephanurus spp., Acrylosto spp., Uncinaria spp., Bunostomum spp., Globocephalus spp., Syngamus spp., Cyathosto a spp. , Metastrongylus spp., Dictyocaulus spp., Muellerius spp., Protostrongylus spp., Neostrongylus spp., Cystocaulus spp., Pneumostrongylus spp. , Spicocaulus spp. , Elaphostrongylus spp. , Parelaphostrongylus spp., Crenosoma spp., Paracrenosa spp., Angiostrongylus spp., Aelurostrongylus spp., Filaroides spp., Parafilaroides spp., Trichostrongylus spp., Haemonchus spp., Ostertagia spp. Marshallagia spp., Coope- ria spp., Nematodirus spp., Hyostrongylus spp., Obeliscoi-des spp., Amidosto um spp., Ollulanus spp. '. From the class of Oxyurids, for example: Oxyuris spp., Enterobius spp., Passalurus spp., Syphacia spp., Aspiculu-ris spp., Heterakis spp. From the Ascarid class, for example: Ascaris spp., Toxascaris spp., Toxocara spp., Parascaris spp., Anisakis spp., Ascaridia spp. From the class of Spirurids, for example: Gnathostoma spp. , Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracuncu-lus spp. From the class of the Filiáridos, for example: Stephanofilaria spp., Parafilaria spp. , Setaria spp., Loa spp., Dirofilaria spp., Litomosoides spp., Brugia spp., Wuchereria spp., Onchocerca spp. From the Gigantohinquine class, for example: Filicollis spp., Moniliformis spp., Macracanthorhynchus spp. ., Prosthenorchis spp. Useful and breeding animals include mammals such as for example cows, horses, goats, pigs, goats, camels, hippos, donkeys, rabbits, deer, reindeer, animals for skin production such as example mink, chinchillas, raccoons, birds such as chickens, geese, ducks, turkeys.

To the laboratory and test animals belong mice, rats, guinea pigs, golden hamsters, dogs and cats. Pet animals and cats belong to entertainment animals. The application can be carried out both prophylactically and therapeutically. The application of the active ingredients is carried out directly or in the form of suitable preparations in an enteral, parenteral, dermal or nasal manner, by treatment of the environment or with the aid of molding bodies containing the active compound, such as, for example, strips, plates, bands, collars, ear tags, limb bands, marking devices. The enteral application of the active compounds is carried out, for example orally, in the form of powders, tablets, capsules, pastes, beverages, granules, orally applicable solutions, suspensions and emulsions, boluses, feed or medicated drinking water. The dermal application is carried out for example in the form of immersion (Dippen), spraying, bathing, washing, pouring (pour-on and spot-on) and dusting. Parenteral application is carried out, for example, in the form of an injection (intramuscular, subcutaneous, intravenous, intraperitoneal) or by implantation.

Suitable preparations are: Solutions such as injectable solutions, oral solutions, concentrates for oral administration after dilution, solutions for use on the skin or in the body cavities, spray formulations, gels, emulsions and suspensions for oral or dermal application as well as for injection; semi-solid preparations; formulations in which the active product is administered in an ointment base or in an oil-in-water or water-in-oil emulsion base; solid preparations such as powders, premixes or concentrates, granulates, pellets, tablets, boluses, capsules; aerosols and inhaled, molded bodies containing the active product. The solutions for injection are administered intravenously, intramuscularly and subcutaneously. Injectable solutions are prepared by dissolving the active compound in a suitable solvent and additives are added, such as solubilizers, acid bases, buffer salts, antioxidants, preservatives. The solutions are filtered sterile and packaged. Solvents which may be mentioned are: physiologically compatible solvents such as water, alcohols such as ethanol, butanol, benzyl alcohol, glycerin, glycol, polyethylene glycols, N-methyl-pyrrolidone, and mixtures thereof. The active compounds can also be dissolved, if appropriate, in physiologically compatible vegetable or synthetic oils which are suitable for injection. Solubilizers which may be mentioned are: solvents which favor the solution of the active compound in the main solvent or prevent its precipitation. Examples are polyvinylpyrrolidone, castor oil, polyoxyethylene-do, polyoxyethylenated sorbitan esters. The preservatives are: benzyl alcohol, trichlorobutanol, esters of p-hydroxybenzoic acid, n-butanol. The oral solutions are used directly. The concentrates are used orally after previous dilution up to the concentration of application. Oral solutions and concentrates are prepared in the manner described above in the case of injectable solutions, and can be desisted to work in a sterile manner. The solutions for use on the skin are smeared, spread, rubbed, splashed or injected. These solutions are prepared in the manner described above in the case of injectable solutions. It may be advantageous to add thickeners in the collection. Thickeners are: inorganic thickeners such as bentonite, colloidal silicic acid, aluminum monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols and their copolymers, acrylates and methacrylates. The gels are applied to the skin or smeared or inserted into the body cavities. The gels are prepared by combining solutions, which have been prepared as described in the case of injectable solutions, with an amount of thickener such that a clear mass with ointment-like consistency is formed. The thickeners indicated above are used as thickeners. The formulations for watering are irrigated or sprayed on limited areas of the skin, the active product penetrating the skin and acting systemically. The watering formulations are prepared by dissolving, suspending or emulsifying the active product in suitable solvents compatible with the skin or solvent mixtures. If necessary, add other auxiliary products such as dyes, resorption-promoting agents, antioxidants, light stabilizers, adhesives. As solvents there may be mentioned: alkanols, glycols, polyethylene glycols, polypropylene glycols, glycerin, aromatic alcohols such as benzyl alcohol, phenyl ethanol, phenoxyethanol, esters such as acetates, butyl alcohol. coughs, benzylbenzoates, ethers such as alkylene glycol alkylene glycols, polypropylene glycol monomethyl ether, diethylene glycol or butyl ether, ketones such as acetone, methyl ethyl ketone, aromatic and / or aliphatic hydrocarbons, vegetable or synthetic oils, DMF, dimethylacetamide, N-methylpi-rolidone, 2, 2 -dimethyl-4-oxy-methylene-l, 3-dioxolane. The dyes are all dyes admitted to be used with animals, which can be dissolved or suspended. The resorption promoting products are for example DMSO, extender oils such as isopropyl myristate, dipropylene glycol pelargonate, silicone oils, fatty acid esters, triglycerides, fatty alcohols. The antioxidants are sulphites or etabisulfites such as potassium bisulfite, ascorbic acid, butylhydroxytoluene, butylhydroanisole, tocopherol. The light-protecting agents are, for example, novantisolic acid. The adhesives are, for example, cellulose derivatives, starch derivatives, polyacrylates, natural polymers such as alginates, gelatins. The emulsions can be used orally, dermally or as injections. The emulsions are of the water-in-oil or oil type in water. They are prepared by dissolving the active compound either in a hydrophobic or hydrophilic phase and homogenizing it with the solvent of the other phase with the aid of suitable emulsifiers and, if necessary, other auxiliaries such as dyes, resorption-promoting products, preservatives, antioxidants, light protection products, products to increase viscosity. As the hydrophobic phase (oils) there may be mentioned: paraffin oils, silicone oils, natural vegetable oils such as sesame oil, almond oil, castor oil, synthetic triglycerides such as caprylic acid glyceride / capric acid, mixed triglycerides with vegetable fatty acids having a chain length of 8 to 12 carbon atoms or with other specially selected natural fatty acids, mixtures of partial glycerides of saturated or unsaturated fatty acids, optionally also containing hydroxyl, mono-, and diglyceride groups of fatty acids with 8/10 carbon atoms. Fatty acid esters such as ethyl stearate, di-n-butyryl adipate, hexyl laurate, dipropylene glycol pelargonate, esters of a branched fatty acid having an average chain length with saturated fatty alcohols having a length of chain from 16 to 18 ato- carbon esters, isopropyl myristate, isopropyl palmitate, esters of caprylic / capric acids of saturated fatty alcohols with a chain length of 12-18 carbon atoms, isopropyl stearate, oleiyl oleate, decyl oleate, ethyl oleate, ethyl lactate, waxy type fatty acid esters, such as synthetic fat of the uropigial gland of the añades, dibutyl phthalate, diisopropyl adipate, mixtures of esters related to the above and others. Fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol, oleyl alcohol. Fatty acids such as, for example, oleic acid and mixtures thereof. As the hydrophobic phase, mention may be made of: Water, alcohols such as, for example, propylene glycol, glycerin, sorbitol and mixtures thereof. As emulsifiers there may be mentioned: nonionic surfactants, for example polyoxyethylenated castor oil, polyoxyethylenated sorbitan monooleate, sorbitan monostearate, glycerin monostearate, polyoxy-yl stearate, alkylphenol polyglycol ether; ampholytic surfactants such as disodium N-lauryl-J-iminodipropionate or lecithin; anionic surfactants such as sodium lauryl sulfate, fatty alcohol ether sulfate, monoethanolamide / dialkylpoetheryl ether orthophosphate monoethanolamine salts; cationic surfactants such as cetyltrimethylammonium chloride. As other auxiliary products there may be mentioned: products for increasing viscosity and emulsion stabilizing products such as carboxymethylcellulose, methyl cellulose and other derivatives of cellulose and starches, polyacrylates, alginates, gelatins, gum arabic, polyvinyl pyrrolidone, polyvinyl alcohol, copolymers of methyl vinyl ether and maleic anhydride, polyethylene glycol, waxes, colloidal silicic acid or mixtures of the indicated products. The suspensions can be used orally, dermally, or as an injection. They are prepared by suspending the active compound in an excipient liquid, if appropriate, with the addition of other auxiliary products, such as wetting agents, dyes, absorption-promoting products, preservatives, antioxidants, and light stabilizers. Suitable excipient liquids are all solvents and homogeneous solvent mixtures. As humectants (dispersants), L S surfactants mentioned above can be mentioned. As additional auxiliary products, those mentioned above may be mentioned.

Semi-solid preparations can be administered orally or dermally. They differ from the suspensions and emulsions described above only because of their higher viscosity. In order to obtain solid preparations, the active compound is mixed with suitable excipients, optionally with the addition of auxiliary products, and brought to the desired shape. Suitable excipients are all physiologically acceptable solid inert products. As such they serve inorganic and organic products. Inorganic products are for example common salt, carbonates such as calcium carbonate, bicarbonates, aluminum oxide, silicic acids, clays, precipitated or colloidal silicon dioxide, phosphates. Organic products are for example sugars, celluloses, food and feed such as sugar powder, animal flour, cereal flours and starches, starches. Auxiliary products are preservatives, antioxidants, dyes, which have already been indicated above. Other suitable auxiliary products are lubricants and fatliquors, such as for example magnesium stearate, stearic acid, talc, bentonite, decomposition promoting substances such as starches or cross-linked polyvinylpyrrolidone, binders such as for example starches, gelatins or linear polyvinylpyrrolidone as well as dry binders such as microcrystalline cellulose. The active products can also be present in the preparations in a mixture with synergists or with other active products which act against the pathogenic endoparasites. Such active compounds are, for example, L-2,3,5,6-tetrahydro-6-phenyl-imidazothiazole, benzyl-zol carbamate, Praziquantel, Pyrantel, Febantel. Preparations ready for application contain the active compound in concentrations of 10 parts per million of 20% by weight, preferably 0.1 to 10% by weight. Preparations that are diluted before application contain the active compound in concentrations of 0.5 to 90% by weight, preferably 5 to 50% by weight. In general it has been found to be advantageous to administer amounts of about 1 to about 100 mg of active product per kg of body weight per day for obtaining effective results. Active ingredient in the following examples was Imidaprid = 1- [(6-ro-3-pyridinyl) methyl] -N-nitro-imidazolidinimine.

Example 1. Formulation SC- (concentrate in suspension): 368 g Imidacloprid 35 g polymer block emulsifier ethylene oxide and propylene oxide. 12 g condensed ditolyl ether sulfonate formaldehyde (emulsifier) 3.5 g water-soluble polyvinyl alcohol 58.0 g NH4C1 116.0 g urea 1.2 g (37% aqueous hydroric acid) 4.6 g xanthan gum 560.5 g distilled water. Example 2. Formulation WP (dispersible powder): 25.0 g Imidacloprid 1.0 g diisobutyl-naphthalene-Na-sulfonate 10.0 g calcium n-dodecylbenzylsulfonate 12.0 g alkylaryl polyglycol ether containing highly dispersed silica 3, 0 g of ditolyl ether sulfonate-formaldehyde condensate (emulsifier) ® 2.0 g Baysilon-E a defoamer containing silicone from Bayer AG. 2.0 g finely divided silicon dioxide and 45, O g kaolin. Example 3. Formulation SL- (concentrate soluble in water). 18.3 g Imidacloprid 2.5 g neutral emulsifier based on alkylaryl polyglycol ether 3.5 g sodium diisooctyl sulfosuccinate 38.4 g dimethyl sulfoxide and 37.5 g 2 -propanol. Example 4. Formulation SL- (water soluble concentrate). 185 g Imidacloprid 5.0 g sodium diisooctyl sulfosuccinate and 76.5 g dimethisulfoxide are mixed with a 100 g shampoo formulation consisting of 44. 4% by weight of Marion AT 50, a triethanolamine salt of alkylbenzenesulfonic acid from Hüls AG 11.1% by weight of Marion A 350, sodium salt of alkyl-benzenesulfonic acid from Hüls AG 3.0% by weight of condensation product of oleic acid and diethanolamine of the firm Hüls AG and 41.5% by weight of polyethylene glycol. Example 5. Spray formulation constituted by 2.0 g Imidacloprid 10.0 g Dimethylsulfoxide 35.0 g 2 -propanol and 53.0 g acetone. Example A. In vivo test against nematodes. Haemonchus contortus / lamb. Lambs experimentally infected with Haemonchus contortus were treated once the parasite preparatory time had elapsed. The active products were applied orally in the form of pure active product in gelatin capsules. The degree of effectiveness is determined by quantitatively counting earthworm eggs with the excrement before and after treatment. A complete stoppage of eggs after treatment means that the worms were expelled or have been so damaged that they no longer produce eggs (effective dose). The active products tested and the active doses (effective dose) can be seen in the following table.

Example B. Example Hymenolepis nana / mouse. Orally infected mice were treated experimentally with infectious eggs of Proglottiden once the preparatory time had elapsed (four times orally for 4 successive days). After 7 days the number of Scolices is determined in the intestine. The activity is calculated according to the formula Number of scolices in - Number of scoli- The control group is in the treated group% of activity = - Number of scolices in the control group. Active product: Imidacloprid; activity: 100% in the case of oral application of 25 mg / kg. It is noted that, in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention. Having described the invention as above, the content of the following is claimed as property:

Claims (4)

1. CLAIMS 1. - Use of agonists and antagonists of the nicotinergic receptors of insect acetylcholine for the fight against endoparasites.
2. 2. Endoparasiticidal agents, characterized in that they have a content in at least one agonist or antagonist of the nicotinergic acetylcholine receptors.
3. 3. - Process for obtaining endoparasiticidal agents, characterized in that they are mixed with extenders and / or surfactants.
4. 4. - Use of endoparasiticide agents to obtain endoparisiticide agents. R E S UM E N Use of agonists and antagonists of the nicotinergic receptors of the acetylcholine of insects for the fight against endoparasites.